Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pipeline at Psych Congress 2025

Core Insights - Axsome Therapeutics, Inc. is showcasing six presentations at Psych Congress 2025, focusing on innovative neuroscience products for CNS disorders [1][6] Group 1: Major Depressive Disorder - Presentation on Auvelity (dextromethorphan 45 mg-bupropion 105 mg) in patients with Major Depressive Disorder, led by Dr. Anita H. Clayton [2] Group 2: Alzheimer's Disease Agitation - Presentation on the efficacy and safety of AXS-05 in Alzheimer's Disease Agitation from the ACCORD-2 Phase 3 study, led by Dr. Jeffrey Cummings [3] Group 3: Narcolepsy - Multiple presentations on AXS-12, including its impact on symptom severity and functional impairment in narcolepsy from the Phase 3 SYMPHONY Trial, led by Dr. Michael Thorpy [5] - ENCORE study results on AXS-12 in narcolepsy, led by Dr. Richard Bogan [5] - Analysis of residual symptom burden in narcolepsy patients satisfied with treatment from the CRESCENDO Survey, led by Dr. Michael Thorpy [5] Group 4: Obstructive Sleep Apnea - Presentation on the effects of Solriamfetol on neuropsychological outcomes in patients with Obstructive Sleep Apnea from the real-world SURWEY study [4] Company Overview - Axsome Therapeutics is focused on developing differentiated products for CNS conditions, with FDA-approved treatments for major depressive disorder, narcolepsy, and obstructive sleep apnea, addressing serious neurological and psychiatric conditions impacting over 150 million people in the U.S. [6]